摘要
目的通过观察复发性口腔溃疡(ROU)患者表皮生长因子(EGF)、E-选择素(E-selectin)水平变化,评价西地碘片联合FE复合酶漱口液治疗的应用价值。方法选取我院于2019年3月至2020年12月收治的160例ROU患者,随机分为对照组和研究组,各为80例。对照组接受FE复合酶漱口液,研究组在此基础上联合西地碘片。对比两组疗效、唾液EGF、E-selectin水平变化、免疫功能,随访5个月,观察两组患者复发情况。结果研究组的临床总有效率高于对照组(P<0.05)。研究组治疗后EGF、E-selectin水平更低(P<0.05)。与对照组相比,研究组治疗后CD8^(+)更低,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)更高(P<0.05)。研究组随访期间的复发率低于对照组(P<0.05)。结论西地碘片联合FE复合酶漱口液治疗ROU患者,可提高机体免疫功能,降低EGF、E-selectin水平,具有较好的临床应用价值。
Objective To observe the changes of epidermal growth factor(EGF)and E-selectin levels in patients with recurrent oral ulcer(ROU),and to evaluate the application value of xideiodine tablets combined with FE compound enzyme gargle in the treatment of ROU.Methods 160 patients with ROU in our hospital during 03/2019-12/2021 were selected for the study,and they were divided into the control group and study group according to the two colors ball method,with 80 cases in each group.The control group received FE compound enzyme gargle,while the study group received cediridium tablets in addition to FE compound enzyme gargle.The curative effect,salivary EGF,E-selectin levels and immune function of the two groups were compared.Patients were followed up for 5 months to observe the recurrence of the two groups.Results The total effective rate of the study group was higher than that of the control group(P<0.05).Compared with the control group,levels of EGF and E-selectin in the study group were lower after treatment(P<0.05).Compared with the control group,CD8^(+)in the study group was lower,and CD3^(+),CD4^(+),CD4^(+)/CD8^(+)were higher after treatment(P<0.05).During the follow-up period,the frontal recurrence rate of the study group was lower than that of the control group(P<0.05).Conclusion Xideiodine tablets combined with FE compound enzyme gargle in the treatment of patients with ROU can improve the immune function and reduce levels of EGF and E-selectin,which has a good clinical application value.
作者
黎炜
郭盼
董彬
LI Wei;GUO Pan;DONG Bin(The Department of Stomatology,Xiyuan Hospital,Chinese Academy of Traditional Chinese Medicine,Beijing 100091,China)
出处
《标记免疫分析与临床》
CAS
2023年第2期237-240,288,共5页
Labeled Immunoassays and Clinical Medicine
基金
北京市卫生科技发展专项基金(编号:J20190125)。